GlassScriptPhysician profile
Lisa W Chriss
NPI 1730178286
$7,921.56
in general payments reported to CMS, 2019-2025
29 companies · $2,193 in 2025
The $2,193 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $128 · 2021: $1,001 · 2022: $1,199 · 2023: $1,318 · 2024: $649 · 2025: $2,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,159.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $995.69 | 2020-2025 | Tryptyr, Centurion, Argos |
| Abbvie INC. | $819.39 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $710.02 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $636.07 | 2019-2021 | |
| Lumenis Be INC | $631.41 | 2025 | M22 |
| Mallinckrodt Hospital Products INC. | $569.07 | 2021-2025 | Acthar |
| Bausch & Lomb Americas INC. | $516.46 | 2022-2025 | Miebo, Doctors Allergy Formula, Vyzulta |
| Sun Pharmaceutical Industries INC. | $509.09 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $364.57 | 2019-2022 | |
| Harrow Eye, LLC | $327.42 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $273.68 | 2023 | Tepezza |
| Amgen INC. | $224.32 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $175.43 | 2021 | |
| Dompe US, INC. | $167.19 | 2020-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $164.41 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $135.97 | 2019-2023 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $121.83 | 2025 | Xdemvy |
| Glaukos Corporation | $105.20 | 2025 | Idosetr, Istent |
| Silk Road Medical, INC. | $92.49 | 2019 | |
| Ocular Therapeutix, INC. | $67.27 | 2023 | Dextenza |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Thea Pharma INC. | $57.17 | 2024-2025 | Iyuzeh |
| Oyster Point Pharma, INC. | $48.87 | 2022-2023 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $33.45 | 2021 | |
| Biotissue Holdings INC. | $32.70 | 2021 | |
| Akorn, INC. | $21.15 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.76 | 2025 | Syfovre |
| Shire North American Group INC | $19.52 | 2019 | |
| Rxsight INC | $17.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Chriss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.